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Abstract Clinical trials have reported reduced cardiovascu-
lar events with certain antihypertensive agents at a rate that
could not be predicted by changes in brachial arterial pres-
sure alone. These findings may be explained, in part, by
pleiotropic effects of these agents and modulation of central
blood pressures. This review focuses on the mechanisms by
which calcium channel blockers exert pleiotropic effects,
both alone and in combination with statins and inhibitors
of the renin-angiotensin system. The essential role of nitric
oxide (NO) in maintaining endothelial function and the
relationship between NO and reactive oxygen species are
discussed in the context of the etiology of hypertension. The
importance of managing global cardiovascular risk is em-
phasized, as hypertension commonly clusters with dyslipi-
demia and loss of glucose control. From a mechanistic
viewpoint, these risk factors contribute to endothelial dys-
function, oxidative stress, and inflammation in a synergistic
fashion. A greater understanding of the mechanisms of
actions of these cardiovascular agents may lead to more
effective drug combinations, to the benefit of individual
patients. Furthermore, by elucidating the biological mecha-
nisms by which cardiovascular risk factors lead to vascular
injury, we may highlight common pathways and identify
novel therapeutic targets.
Keywords Calciumchannelblockers .Endothelial
function .Nitricoxide .Centralaorticpressure .Statins .
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Introduction
Blood pressure is a primary and independent risk factor for
cardiovascular disease [1]. By convention, blood pressure is
measured using a sphygmomanometer (manual or automatic)
over the brachial artery. The vast majority of the evidence
supportingthebenefitsofbloodpressurereductionisbasedon
brachial blood pressure measurements [2].
Over the last 10 years, several antihypertensive drug
treatment trials have shown an unexpected discrepancy be-
tween reduction in brachial blood pressure and observed
clinical outcomes. In the Heart Outcomes Prevention Eval-
uation (HOPE) [3], the Losartan Intervention For Endpoint
reduction (LIFE) in hypertension [4], and the Australian
National Blood Pressure 2 (ANBP2) [5] trials, the observed
clinical benefits tended to be greater than those expected
from the decrease in brachial blood pressure. This may be
explained by the pleiotropic effects of the antihypertensive
drugs used in these trials. In particular, the beneficial effects
of these agents on endothelial function and its vascular
manifestations, such as changes in central aortic pressure
and atheroma development.
It has been proposed that central aortic pressure may have
more pathophysiological relevance than peripheral blood
pressure as a marker for the development of cardiovascular
disease [6￿, 7]. Central aortic pressure is determined by the
combination of cardiac output and peripheral vascular resis-
tance that is modulated by arterial stiffness along with the
timing and magnitude of pressure wave reflections in the
arterial tree. The pressure wave generated by the left ventri-
cle during cardiac systole travels through the vessels until it
reaches the small muscular arteries and arterioles where it is
reflected [8]. The pressure waveform at any point in the
arterial tree is therefore the sum of both forward and back-
ward waveforms. When the large arteries are healthy and
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in the proximal aorta during diastole, augmenting diastolic
blood pressure and aiding coronary perfusion. However,
when the large arteries are stiff, pulse wave velocity
increases, accelerating both incident and reflected waves
[8]. This results in the reflected wave merging with the
incident wave in systole, thus augmenting central aortic
systolic rather than diastolic pressure. Thus, central aortic
stiffness contributes directly to a wide pulse pressure with
higher systolic and lower diastolic blood pressure. Further-
more, the state of the vasculature in the peripheral circula-
tion also affects the proportion of the incident wave that is
reflected, thus affecting central pressure.
Observational studies have shown that the difference
between brachial and central arterial pressures can vary by
between 2 and 33 mm Hg [9, 10]. Furthermore, different
antihypertensive drugs have been shown to have similar
effects on brachial blood pressure, but different effects on
central aortic pressure [6￿, 11–13]. This may, in part, explain
why central aortic pressure has been shown to have superior
prognostic value with respect to cardiovascular events than
brachial blood pressure in clinical studies [6￿, 11–13].
The Conduit Artery Function Evaluation (CAFE) study
[6￿], was a substudy of the Anglo-Scandinavian Cardiac
Outcomes Trial (ASCOT). In ASCOT, patients with hyper-
tension and at least three additional cardiovascular risk
factors were randomized to an atenolol plus
bendroflumethiazide-based treatment regimen or an amlodi-
pine plus perindopril-based regimen. The CAFE study
recruited 2,199 ASCOT patients after the first year of AS-
COT follow-up (mean age of the cohort at baseline,
63 years) and followed them for up to 4 years. Radial artery
applanation tonometry and pulse wave analysis were used to
derive central aortic pressures and hemodynamic indices.
Throughout follow up, derived central aortic systolic pres-
sure was substantially lower in the amlodipine-based treat-
ment group compared with the atenolol-based treatment
group (area under the curve [AUC] difference, 4.3 mm
Hg; 95 % confidence interval [CI], 3.3 to 5.4; P<0.0001),
whereas brachial systolic blood pressure was similar be-
tween the two treatment arms (AUC difference, 0.7 mm
Hg; 95 % CI, –0.4 to 1.7; P00.2). Furthermore, central
pulse pressure (PP) was associated with total cardiovascular
events and procedures and the development of renal im-
pairment (unadjusted P<0.0001; adjusted for baseline val-
ues P<0.05). The CAFE study demonstrated that
antihypertensive drugs can have different effects on central
aortic pressure despite similar brachial blood pressure
measurements. The authors of the CAFE study proposed
that their study elucidated a plausible mechanism to explain
the superior clinical outcomes observed in the amlodipine-
based treatment arm of ASCOT. They also speculated that
central aortic pressure measurements may provide an
explanation for the differences observed in other major
outcome trials including LIFE [4] and HOPE [3].
The findings of the CAFE study [6￿] supported those of
the Preterax in Regression of Arterial Stiffness in a Con-
trolled Double-Blind Study (REASON) [13], which
reported that peripheral blood pressure measurements did
not accurately reflect changes in central aortic pressure
following treatment with different antihypertensive drugs.
The finding that central pressure and wave reflection indices
are strong independent predictors of all-cause and cardio-
vascular mortality has also been demonstrated in high-risk
patient groups, including those with end-stage renal failure
(Table 1)[ 11, 12].
These findings are complemented by the results of the
Strong Heart Study [7, 14], a population-based, longitudinal
study among 3,520 American Indians (mean age 58 years)
followed for a mean of 4.8 years. This study reported that a
central PP greater than 50 mm Hg and not brachial PP was
an independent predictor of cardiovascular outcomes, re-
gardless of age, sex, or diabetes. Furthermore, central PP
was strongly associated with carotid intima-media thick-
ness, plaque score, and vascular mass, and was a stronger
predictor of cardiovascular events than brachial blood
pressure.
Together, these studies provide evidence to support the
hypothesis that central aortic pressure may more accurately
reflect the load on the central vasculature than brachial
blood pressure (Table 1)[ 11–13, 6￿, 7]. It is therefore a
reasonable proposition that central pressure relates more
directly to target organ damage and clinical cardiovascular
disease. This has led to the suggestion that central and not
brachial blood pressure should be a treatment target for
cardiovascular disease risk reduction strategies [7]. The
mechanisms by which some antihypertensive drugs, includ-
ing calcium channel blockers, affect the vasculature and lead
to differential lowering of central and brachial blood pres-
sure may be because of their effects on endothelial function,
as will now be discussed in more detail.
Endothelial Dysfunction and the Role of NO
Endothelial dysfunction, a key feature of hypertension, is
primarily caused by enhanced oxidative stress, but other
important contributors include age, vascular injury, meta-
bolic disorders, deficiencies in essential substrates (e.g., L-
arginine), and enzyme cofactors (e.g., tetrahydrobiopterin
[BH4]) [15]. Endothelial dysfunction is characterized by
reduced nitric oxide (NO) bioavailability resulting in in-
creased vascular resistance and reduced sensitivity to nor-
mal stimuli of vasodilation, such as shear stress and
acetylcholine [16].
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lium and has a key role in regulating vasomotor tone. In
addition, NO has atheroprotective effects by reducing
smooth muscle cell proliferation and migration, adhesion
of leukocytes to the endothelium, and platelet aggregation
[17]. NO is derived from the conversion of L-arginine to L-
citrulline by the enzymatic activity of endothelial NO syn-
thase (eNOS). The activity of this electron transport enzyme
requires calcium/calmodulin, flavin adenine dinucleotide,
flavin mononucleotide, and BH4 as cofactors.
Normal physiologic levels of NO increase vasodilation
and interfere with the atherothrombotic process, thereby
helping to maintain a healthy circulatory system. The net
concentration of NO in the circulation is dependent on a
balance between the enzymatic production of NO through the
activity of eNOS and the production of superoxide (O2
–)[ 17].
Many factors can influence eNOS activity, but studies
have shown that its enzymatic cofactor BH4 has a particu-
larly important role [18–20]. When levels of BH4 are insuf-
ficient eNOS cannot couple the reduction of molecular
oxygen with the oxidation of L-arginine. This results in
the generation of O2
– rather than NO [18–20]. This process
is known as “eNOS uncoupling” (Fig. 1). Oxidative modi-
fication of BH4 by various oxidases is a leading reason for
abnormal low levels in the cell.
Reactive oxygen species (ROS) are also generated in the
vasculature by oxidases such as NAD(P)H oxidase that
contribute to oxidative stress [19]. In the presence of exces-
sive levels of O2
–, NO is rapidly converted to peroxynitrite
(ONOO
–) resulting in decreased NO bioavailability and
further impairment of endothelium-mediated vasodilation.
Furthermore, ONOO
– molecules themselves are highly re-
active and oxidize lipids, cause cellular injury, and enhanced
arterial contraction (Fig. 1)[ 21￿].
Animal models have shown that mice deficient in ROS-
generating enzymes have lower blood pressure levels com-
pared with wild-type animals [22]. Further studies found
that, compared with normotensive rats, spontaneously hy-
pertensive rats had lower NO bioavailability despite in-
creased levels of eNOS [23]. The effects were even more
pronounced after induction of diabetes among the hyperten-
sive animals [21￿]. The results were consistent with studies
in rats that developed hypertension after aortic banding [24].
The findings of reduced NO bioavailability, despite in-
creased levels of eNOS observed in these studies, may be
explained by the increased production of O2
– by uncoupled
eNOS. Glucose intolerance is also believed to impair eNOS
activity directly through enhanced oxidative stress.
In a human tissue study comparing endothelial cells from
healthy African American and Caucasian donors, those of
Table 1 Studies reporting differences in measured brachial and central blood pressure that may explain cardiovascular outcomes
Study Measurements Patient population Key result
Strong Heart Study
(2007, 2009) [7, 14]
Sphygmomanometer to measure
brachial BP. Radial applanation
tonometry to determine central BP
Population-based, longitudinal
study among 3,520 American
Indians followed for a mean
of 4.8 years
Central PP was strongly associated
with carotid intima-media thickness,
plaque score, and vascular mass.
Central PP was an independent
predictor of CVoutcomes
CAFE (2006)
[6￿]
Semiautomated oscillometric device to
measure brachial BP. Radial artery
applanation tonometry and pulse wave
velocity analysis to derive central aortic
pressure and hemodynamic indexes
Substudy of the ASCOT study. 2,199
patients with hypertension and ≥3
additional CVrisk factors previously
randomized to an amlodipine
or atenolol-based regimen followed
for up to 4 years
Central aortic systolic BP was lower
in the amlodipine versus atenolol arm
throughout follow-up (AUC
difference 4.3 mm Hg, 3.3 to 5.4,
P<0.0001). Brachial systolic BP
similar (AUC difference 0.7 mm Hg,
–0.4, 1.7, P=0.2). May explain
lower CVevents in amlodipine arm
REASON
(2004) [13]
Sphygmomanometer to measure
brachial BP. Pulse wave velocity
analysis and pattern of wave reflections
to derive central aortic pressure
375 patients with hypertension
randomized to atenolol
or perindopril+indapamide,
followed for 1 year
Treatment with perindopril+
indapamide decreased brachial and
central systolic BP significantly more
than atenolol. In the perindopril+
indapamide group the difference
between brachial and central systolic
BP was 8.28±1.53 mm Hg versus
0.29±1.61 mm Hg in the atenolol
group
Safar (2002) [12],
London (2001) [11]
Aortic pulse wave velocity measurement
and determination of arterial wave
reflection by applanation tonometry
on the common carotid artery
180 patients with end-stage
renal failure followed for
a mean of 4.3 years. 40 CV
and 30 non-CVevents occurred
Aortic pulse wave velocity, increased
augmentation index and carotid PP,
were independent predictors
of all-cause and CV mortality
ASCOT Anglo-Scandinavian Cardiac Outcomes Trial; AUC area under the curve; BP blood pressure; CAFE Conduit Artery Function Evaluation;
CV cardiovascular; PP pulse pressure; REASON Preterax in Regression of Arterial Stiffness in a Controlled Double-Blind Study
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NO despite higher levels of eNOS [25]. This paradox was
attributed to excessive O2
– generation by NAD(P)H oxi-
dase, which contributes to increased ONOO
– formation
and uncoupled eNOS activity [25]. These results are con-
sistent with studies reporting differences in endothelial-
dependent vasodilation in African American subjects com-
pared with age- and gender-matched Caucasians [26].
Reduced NO bioavailability may partly explain the
higher rates of hypertension observed among African Amer-
icans compared with Caucasians in various surveys [27].
This has clinical importance as drug treatments that enhance
endothelial NO production may be of particular benefit in
these populations.
The finding of a relationship between reduced
endothelial-derived NO and increased oxidative stress led
to the design of the A-HeFT study (African American Heart
Failure Trial) [28]. That trial showed that the addition of
isosorbide dinitrate and hydralazine to conventional therapy
reduced relative 1-year mortality by 43 % among African
American subjects with advanced heart failure [28]. Isosor-
bide dinitrate is an organic nitrate that directly increases
vascular NO levels, whereas hydralazine is a vasodilator
with antioxidant activity that may scavenge oxyradical spe-
cies, including O2
–. This adds further support to the theory
that agents that enhance NO bioavailability while reducing
nitroxidative stress may have important benefits in this
population.
Fig. 1 Targeting mechanisms –
a global approach to
cardiovascular risk
management. eNOS,
endothelial nitric oxide
synthase; BH4,
tetrahydrobiopterin; FAD,
flavin adenine dinucleotide;
FMN, flavin mononucleotide;
Ca
2+, calcium; O2, oxygen;O 2
–,
superoxide, NO, nitric oxide;
ONOO
–, peroxynitrite
296 Curr Hypertens Rep (2012) 14:293–303Table 2 Outcome trials using calcium channel blockers
Study Design/drug Patient population Key result
ACCOMPLISH
(2008) [48￿]
Double-blind, randomized trial.
Benazepril + amlodipine or
benazepril + hydrochlorothiazide.
Mean follow-up 36 months.
11,506 patients with
hypertension at high risk
of CVevents.
Compared with benazepril + hydrochlorothiazide,
fewer individuals on benazepril + amlodipine
had a primary endpoint (death from CV causes,
nonfatal MI, nonfatal stroke, hospitalization for
angina, resuscitation after sudden cardiac arrest,
and coronary revascularization) HR, 0.80; 95 %
CI, 0.72 to 0.90; P<0.001. For the secondary
endpoint of death from CV causes, nonfatal MI,
and nonfatal stroke, HR 0.79; 95 % CI, 0.67 to
0.92; P=0.002.
ASCOT-BPLA
(2005) [47￿]
Open-label, randomized trial.
Amlodipine ± perindopril-based
regimen or atenolol ±
bendroflumethiazide-based
regimen. Mean 5.5 year follow-up.
19,257 patients with
hypertension and ≥3
additional CV risk factors.
Compared with the atenolol-based regimen, fewer
individuals on the amlodipine-based regimen
had a primary endpoint (nonfatal MI and fatal
CHD) HR, 0.90; 95 % CI, 0.79 to 1.02;
P=0.1052; fatal and nonfatal stroke, HR, 0.77;
95 % CI, 0.66 to 0.89; P=0.0003; total CV
events and procedures, HR, 0.84; 95 % CI, 0.78
to 0.90; P<0.0001; all-cause mortality,
HR, 0.89; 95 % CI, 0.81 to 0.99; P=0.025.
CAMELOT
(2004) [46]
Double-blind, placebo-controlled,
randomized trial. Amlodipine,
enalapril, or placebo. 24 month
follow-up.
1,991 patients with CAD
and DBP <100 mm Hg.
Compared with placebo, there was a 31 %
reduction in CVevents in the amlodipine group
(P=0.003) and a 15 % reduction in the enalapril
group (P=0.16). In the amlodipine group, IVUS
showed evidence of slowing atherosclerosis
progression.
VALUE
(2004)[45]
Double-blind, parallel-group,
randomized trial. Valsartan
or amlodipine. Mean follow-up
4.2 years.
15,245 patients with
hypertension at high risk
of cardiac events.
No difference in the primary outcome (cardiac
mortality and morbidity) between treatment
groups, HR 1.04; 95 % CI, 0.94 to 1.15;
P=0.49. BP reduced by both treatments,
but amlodipine had greater effect especially
in the early period. Amlodipine was superior
to valsartan at preventing MI and angina.
INVEST
(2003)[44]
Open-label, blinded endpoint,
randomized trial. Verapamil
or atenolol. Mean follow-up
2.7 years.
22,576 patients with
hypertension and CAD.
No difference in the primary outcome
(first occurrence of all-cause mortality,
nonfatal MI or nonfatal stroke) between
treatment groups, RR 0.98; 95 % CI 0.90-1.06.
CONVINCE
(2003)[43]
Double-blind, randomized trial.
Verapamil versus atenolol
or hydrochlorothiazide. Mean
follow-up 3 years.
16,602 patients with
hypertension and ≥1
additional CV risk factor.
No difference in the primary outcome
(first occurrence of stroke, MI, or CV-related
death) between treatment groups, HR 1.02;
95 % CI, 0.88 to 1.18; P=0.77.
ALLHAT
(2002)[42]
Double-blind, randomized trial.
3 treatment groups: chlorthalidone;
amlodipine; lisinopril.
Mean follow-up 4.9 years.
33,357 patients with
hypertension and ≥1
additional CHD risk factor.
No difference in the primary outcome (fatal CHD
or nonfatal MI) between treatment groups.
Compared with chlorthalidone: RR for
amlodipine 0.98; 95 % CI, 0.90 to 1.07;
lisinopril 0.99; 95 % CI, 0.91 to 1.08.
NORDIL
(2000)[40]
Open-label, blinded endpoint,
randomized trial. Diltiazem
or diuretics ± beta-blockers.
Mean follow-up 4.5 years.
10,881 patients with DBP
≥100 mm Hg.
No difference in the primary outcome (fatal and
non-fatal stroke, MI, CV death) between the 2
groups, RR 1.00; 95 % CI, 0.87 to 1.15; P=0.97.
INSIGHT
(2000)[39]
Double-blind, randomized trial.
Nifedipine or co-amilozide.
Follow-up 3 years after recruitment
of the last patient.
6,321 patients with
hypertension and ≥1
additional CV risk factor.
No difference in the primary outcome (CV death,
MI, heart failure, or stroke) between the 2 groups,
RR, 1.10; 95 % CI, 0.91 to 1.34; P=0.35.
PREVENT
(2000) [41]
Double-blind, placebo-controlled,
randomized trial. Amlodipine
or placebo. 36-month follow-up.
825 patients with CAD. No difference in coronary stenosis between the
amlodipine and placebo group. Amlodipine
slowed the progression of carotid artery
atherosclerosis (IMT: amlodipine −0.0126
versus placebo +0.033; P=0.007) and was
associated with fewer hospitalizations
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strongly implicated in the etiology of hypertension, and
drugs that have both antihypertensive and antioxidant prop-
erties may be more effective at reducing blood pressure and
subsequent pathology. Indeed, improving NO bioavailabili-
ty may be an important treatment goal in the management of
hypertension (Fig. 1).
Effect of Calcium Channel Blockers on Endothelial
Function
Dihydropyridine (DHP)-type calcium channel blockers
(CCBs) reversibly inhibit calcium entry into cardiac and
vascular smooth muscle cells by binding to L-type
voltage-sensitive calcium channels [29]. This decreases in-
tracellular calcium concentrations, resulting in smooth mus-
cle cell relaxation. In addition, CCBs have several
pleiotropic effects. Of particular importance, certain DHP-
type CCBs have been shown to modify endothelial function
by enhancing eNOS activity, resulting in increased NO
production [29, 30]. Studies have also suggested that some
of these drugs increase the antioxidant capacity of the en-
dothelium by scavenging O2
– [29, 30]. This further protects
the endothelium by reducing the availability of free radicals
to react with NO. The antioxidant activity is attributed to
CCBs’ high lipophilicity, and a chemical structure that
facilitates proton-donation and resonance-stabilization
mechanisms that inhibit the free-radical reaction [30, 31].
In animal models, the CCB amlodipine has been shown
to increase eNOS activity and its mRNA level in hyperten-
sive rats [32]. In coronary microvessels isolated from canine
cardiac tissue, amlodipine caused a dose-dependent release
of nitrite, the hydration product of NO [33￿]. The effects of
amlodipine on both nitrite release and the NO-dependent
regulation of cardiac oxygen consumption were inhibited
with specific antagonists of eNOS such as L-N
G-monome-
thylarginine (L-NMMA). Under identical conditions, other
DHP and non-DHP-type CCBs, including nifedipine and
diltiazem, failed to reproduce these effects.
In clinical studies among patients with essential hyper-
tension, nifedipine has been shown to attenuate circulating
plasma levels of lipoperoxides and isoprostanes, increase
plasma antioxidant capacity, and restore NO bioavailability
[34]. In the Elevation of Nifedipine and Cerivastatin on
Recovery of Endothelial Function (ENCORE) I and EN-
CORE II studies, nifedipine significantly improved NO-
mediated coronary endothelial function in patients with
coronary artery disease [35, 36].
The safety and efficacy of CCB therapy and its role in
reducing cardiovascular events and procedures has been dem-
onstrated in several large clinical studies among patients with
and without established cardiovascular disease [37–46, 47￿,
48￿].KeyfindingsfromthesestudiesaresummarizedinTable2
for both DHP-type CCBs and other members of this drug class.
Table 2 (continued)
Study Design/drug Patient population Key result
for unstable angina
and coronary revascularization.
SYST-EUR
(1997) [38]
Double-blind, placebo-controlled,
randomized trial. Nitrendipine
or placebo. Median
follow-up 2 years.
4695 patients with isolated
systolic hypertension
(SBP ≥160 mmHg
and DBP <95 mmHg).
Compared with placebo, nitrendipine reduced
the total rate of stroke by 42 % (P=0.003);
nonfatal stroke by 44 % (P=0.007) and all
fatal and nonfatal cardiac events by 26 %
(P=0.03).
MIDAS
(1996) [37]
Double-blind, randomized trial.
Isradipine or hydrochlorothiazide.
3 year follow-up.
883 patients with
hypertension
No difference in the rate of progression of mean
maximum IMT (P=0.68) between treatment
groups. Higher (but non-significant, P=0.07)
incidence of major vascular events (MI, stroke,
heart failure, angina, sudden death)
in the isradipine versus the hydrochlorothiazide
group (25 vs 14 events).
ACCOMPLISH Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension study; ASCOT-BPLA
Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm; CAMELOT Comparison of Amlodipine versus Enalapril to Limit
Occurrences of Thrombosis study; VALUE, Valsartan Antihypertensive Long-term Use Evaluation; INVEST, The International Verapamil-
Trandolapril Study; CONVINCE, Controlled Onset Verapamil Investigation of Cardiovascular End Points; ALLHAT, The Antihypertensive and
Lipid-Lowering Treatment to Prevent Heart Attack Trial; NORDIL, the Nordic Diltiazem study; INSIGHT, Intervention as a Goal in Hypertension
Treatment; PREVENT Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial; SYS-EUR, Systolic Hypertension in Europe;
MIDAS, Multicenter Isradipine Diuretic Atherosclerosis Study.
CAD coronary artery disease; CHD coronary heart disease; CI confidence interval; CV cardiovascular; DBP diastolic blood pressure; HR hazard
ratio; IMT intimal-media thickness; IVUS intravascular ultrasound; MI myocardial infarction; SBP, systolic blood pressure
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Hypertension commonly clusters with other cardiovascular
risk factors, including dyslipidemia and diabetes, greatly
increasing an individual’s risk of an event [49, 50]. From a
mechanistic viewpoint, these risk factors act synergistically
to exacerbate endothelial dysfunction, oxidative stress, and
inflammation, thereby accelerating the atherosclerotic pro-
cess [51].
Although controversy remains over the optimal choice of
antihypertensive drug therapy, hypertension management
guidelines agree that most patients may require at least
two antihypertensive drugs to reach the currently recom-
mended blood pressure targets [52–54]. In addition, many
patients with hypertension also benefit from concurrent
statin therapy [52–54]. Thus most patients with hyperten-
sion require multiple drug treatment regimens to manage
their cardiovascular risk.
A greater understanding of the mechanisms of actions of
antihypertensive and lipid-lowering drugs may lead to more
effective drug combinations with respect to clinical out-
comes. This review focuses on the combination of CCBs
with statins and CCBs in combination with drugs that affect
the renin-angiotensin system (RAS).
Rationale for Combining Calcium Channel Blockers
and Statins
Both CCBs and statins have been shown to reduce cardio-
vascular events in large clinical outcome trials [45, 46, 55,
56, 47￿, 48￿]. ASCOT highlighted a potential synergy be-
tween co-administered amlodipine and atorvastatin in terms
of the cardio-protective effect of this drug combination [57].
In ASCOT, those randomized to amlodipine plus atorvasta-
tin had a 53 % reduction in coronary heart disease events
compared with a 16 % reduction among those randomized
to atenolol plus atorvastatin. This could not be explained by
differences in blood pressure and lipid parameters between
the two treatment regimens. Furthermore, the significant
benefits of the amlodipine plus atorvastatin combination
were observed within the first 3 months of treatment (P0
0.02) [57]. This is suggestive of a functional rather than a
structural change to the vasculature.
The findings from ASCOT [57] may be explained, in
part, by observations from the AVALON Arterial Wall Com-
pliance (AWC) trial [58]. In the AWC trial, 668 patients
(61 % male, mean age 55 years) with concomitant hyper-
tension and dyslipidemia were randomized to one of four
treatment groups (placebo, amlodipine 5 mg, atorvastatin
10 mg, co-administered amlodipine 5 mg and atorvastatin
10 mg) [58]. Arterial compliance was assessed every
4 weeks. After 8 weeks of treatment, there was a 19.3 %
improvement in small artery compliance in the co-
administered amlodipine and atorvastatin group compared
with 11.7 % in the amlodipine alone group (P00.03), 3.1 %
in the atorvastatin alone group (P<0.001), and −1.3 % in the
placebo group (P<0.0001). After 28 weeks of treatment, the
greatest improvement in small artery compliance remained
among those taking co-administered amlodipine and ator-
vastatin (P<0.05) [58]. The observation that combination
therapy had a more than additive effect on small artery
compliance is consistent with an improvement in the mech-
anisms that control vascular function [59￿]. Indeed, the
authors of the AWC trial proposed that their study provided
evidence that the synergistic effects of co-administered
amlodipine and atorvastatin may be mediated by endothelial
function [58].
ThishypothesisissupportedbytheresultsoftheENCORE
I study that compared NO-mediated endothelial function
among343 patientswithcoronaryarterydisease [35].Patients
were randomized to 6 months treatment with placebo, ceri-
vastatin 0.4 mg/day, nifedipine 30 to 60 mg/day, or their
combination. Endothelial function was assessed by infusing
acetylcholine into a coronary segment and measuring luminal
diameter by quantitative angiography. In the most constricted
segment, nifedipine but not cerivastatin, significantly reduced
acetylcholine-induced vasoconstriction by 18.8 % (P<0.05,
compared with placebo). The combination of nifedipine and
cerivastatin also reduced acetylcholine-induced vasoconstric-
tion by 11 %, but this only reached statistical significance
when all coronary segments were analyzed together. After
cerivastatin was withdrawn from the market in 2001, the
ENCORE study design was modified to compare nifedipine
with placebo [36]. In ENCORE II, all patients were eligible
for statin therapy at the discretion of their physician. In addi-
tion to measuring changes in luminal diameter, intravascular
ultrasound (IVUS) was used to assess change in plaque vol-
ume. Overall, 454 patients were randomized and followed for
18–24 months. Compared with placebo, nifedipine plus back-
ground statin therapy significantly improved coronary endo-
thelial function in the most constricted segment (difference in
luminal diameter 6.3 %, 95 % CI 1.6 to 10.9; P00.0088).
However,comparedwithplacebo,nifedipineplusbackground
statin therapy did not have a significant effect on coronary
plaque volume as measured by IVUS. Together the ENCORE
studies add to the evidence that CCB plus statin therapy
improves NO-mediated endothelial function [35, 36].
From a mechanistic perspective, synergy between CCBs
and statins is plausible, as these drugs have complementary
chemical structures. Atorvastatin has negative polarity asso-
ciated with its heptanoic side chain, whereas amlodipine is
distinct among the DHPs in having a positive charge on its
aminoethoxy side chain [31, 60, 61]. Both amlodipine and
atorvastatin are lipophilic and share high affinity for the cell
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centration of these drugs is much higher in the cell mem-
brane than in the surrounding aqueous environment [31, 60,
61]. These properties may facilitate interactions with novel
receptor sites in vascular cell membranes, and contribute to
explaining the superior clinical outcomes observed when
these drugs are co-administered. This hypothesis was eval-
uated in a study using human umbilical vein endothelial
cells (HUVEC) [59￿]. The combination of amlodipine and
atorvastatin directly stimulated NO release, which was
about twofold greater than the sum of their separate effects
(P<0.05). This was attributed to enhanced eNOS function
and expression along with decreased levels of cytotoxic
ONOO
–. Following low density lipoprotein (LDL) enrich-
ment there was a 60 % reduction in NO production in the
HUVEC and an almost twofold increase in ONOO
–. Treat-
ment with the combination of amlodipine and atorvastatin
partially reversed the adverse effects of LDL, including a
90 % increase in NO and a 50 % reduction in ONOO
–.
Small angle X-ray diffraction analysis indicated that both
amlodipine and atorvastatin are lipophilic and share a com-
mon membrane location [59￿]. This study provides evidence
to suggest the observed synergy between these drugs may be
explained by electron transport mechanisms that facilitate
antioxidant activity in the cell membrane related to their
complementary locations.
Rationale for Combining CCBs and Drugs that Affect
the RAS
The RAS has an important role in blood pressure control by
regulatingbloodvolumeand peripheralvascularresistance. In
brief, in response to the release of renin from the kidneys, the
circulating substrate angiotensinogen is converted to angio-
tensin I. The angiotensin-converting enzyme (ACE) in the
vascular endothelium cleaves off two amino acids to form
the octapeptide, angiotensin II (Ang II). Ang II binds to
angiotensin II type-1 (AT1) receptors in vascular smooth mus-
cle cells, promoting vasoconstriction and increasing peripher-
al vascular resistance. Ang II also stimulates the release of
various hormones including aldosterone and vasopressin,
which act on the kidneys to increase sodium and fluid reten-
tion. Ang II also facilitates norepinephrine release from sym-
pathetic nerve endings and inhibits its reuptake, thereby
enhancing sympathetic adrenergic function. The interaction
between Ang II and AT1 receptors also activates signal trans-
duction mechanisms that promote oxidative stress, inflamma-
tion, cell proliferation, and fibrosis [62]. Studies have shown
that Ang II activates NAD(P)H oxidase in endothelial and
vascularsmoothmusclecells.Thisresultsinthe productionof
O2
– and other ROS, and contributes directly to reduced NO
bioavailability and endothelial dysfunction [63].
Blocking the RAS with ACE inhibitors and angiotensin
receptor blockers (ARBs) has been demonstrated to improve
endothelial function and increase NO bioavailability in
mechanistic [64–67] and clinical [68–70] studies.
In an animal model using infarcted adult male Sprague–
Dawley rats, treatment with the ARB candesartan, enhanced
vasorelaxation by increasing NO bioavailability via an AT2
receptor mediated upregulation of eNOS [64]. A complemen-
tary in vitro study, using the ARBs losartan and valsartan,
stimulated NO release from both platelets and human umbil-
ical vein endothelial cells in a dose-dependent manner. How-
ever, there was more than 70 % greater potency in NO release
in platelets than endothelial cells. Furthermore, the degree of
inhibitionofplateletadhesionandaggregationbylosartanand
valsartan was closely correlated with the level of NO produc-
tion [65]. In an animal model using isolated coronary arterio-
les from pigs, Ang II was shown to evoke AT1 receptor-
mediated vasoconstriction and AT2 receptor-mediated vasodi-
lation. At the vascular level, Ang II was shown to impair
endothelium-dependent NO-mediated dilation attributable to
elevated O2
– production via AT1 receptor activation of NAD
(P)H oxidase. The authors of this study commented that their
results may partly explain why impaired coronary flow is
associated with upregulation of the RAS [66]. The long-term
effect of the ARB valsartan on endothelial function and vas-
cular structural changes in the aorta was explored in hyper-
cholesterolemic rabbits. Treatments with 3 and 10 mg/kg per
dayofvalsartanreducedintimallesionto2.4±0.7 %and2.7±
0.9 %, respectively (P<0.05) and increased lumen area. The
authors suggested that AT1 receptor antagonists, besides their
antihypertensive effects,could alsohavea roleinreducingthe
development of atherosclerosis [67].
The results of these mechanistic studies were consistent
with the results from clinical studies [68–70]. In an active-
controlled, randomized trial, 35 patients with coronary artery
disease received 4 weeks of treatment with either an ACE
inhibitor (ramipril 10 mg/day) or ARB (losartan 100 mg/day).
NO-mediated vasodilation of the radial artery was determined
before and after intra-arterial L-NMMA infusion. NO-
mediated vasodilation was increased by more than 75 % after
treatment with ramipril and losartan (each group P<0.01)
[68]. These results were consistent with a double-blind,
placebo-controlled trial among 60 patients with essential hy-
pertension who received 6 weeks of treatment with either an
ARB (valsartan 80 mg/day), a diuretic (hydrochlorothiazide
25 mg/day), or placebo. NO production was assessed using
forearm blood flow techniques. There were similar reductions
in brachial blood pressure in both active treatment arms (P<
0.001). However, patients in the ARB group had significantly
improvedvasoconstrictiveresponsetoL-NMMA, whereas no
effect was seen in the diuretic and placebo groups [69].
Together, these clinical studies suggest that agents that block
the RAS may improve endothelial function by increasing NO
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patients with and without type 2 diabetes, showed that treat-
ment with valsartan 80 mg/day for 8 weeks significantly
decreased monocyte and endothelial cell activation markers
among those with diabetes, but not among those without
diabetes [70]. This study highlights the importance of using
complex disease models to explore mechanisms of actions,
because focusing on single-risk-factor models may miss im-
portant biological pathways.
There is a growing body of evidence to suggest that DHP-
type CCBs and RAS inhibitors have additional beneficial
effects when used in combination. For example, in an animal
model using Dahl salt-sensitive rats, the combination of CCB
plus ACE inhibitor was more effective than either monother-
apy in normalizing systolic blood pressure and proteinuria
[71]. This study was complimented by a rat myocardial in-
farction model that showed that treatment with the CCB
amlodipine plus ACE inhibitor benazepril increased NO pro-
duction and decreased inflammatory markers. In contrast,
treatment with the diuretic hydrochlorothiazide had no effect
on these indicators of endothelial dysfunction [72].
In clinical studies, the combination of CCBs with an ACE
inhibitorversus a CCB alonehasbeen shown to increase flow-
mediated dilation, a surrogate biomarker of endothelial func-
tion [73]. As previously described, the CAFE study [6￿]d e m -
onstrated that the benefits of the CCB plus ACE inhibitor
combination may extend beyond brachial blood pressure low-
ering and have a positive impact on central blood pressure
hemodynamics [6￿].Furthermore,outcometrialshavereported
that these beneficial effects may translate into reduced cardio-
vascular endpoints. The ASCOT-BPLA study showed that
treatment with an amlodipine plus perindopril-based regimen
prevented more major cardiovascular events than an atenolol
plus bendroflumethiazide-based regimen [47￿]. The ACCOM-
PLISH study showed that treatment with benazepril plus amlo-
dipine was more effective at preventing cardiovascular events
than treatment with benazepril plus hydrochlorothiazide [48￿].
Together, these mechanistic and clinical studies demonstrate
the pleiotropic effects of the combination of CCB plus RAS
blockade on enhanced NO bioavailability and reduced oxida-
tive stress. Understanding the complementary mechanisms of
actions of these drugs forms the rationale for combining differ-
ent antihypertensive agents to enhance their therapeutic effects.
Conclusions
This review has explored the pleiotropic effects of CCBs
alone and in combination with statins and RAS inhibitors.
The mechanisms by which these drugs exert their beneficial
effects on endothelial and vascular function have been de-
scribed, with a particular focus on the effects on NO-
mediated vasodilation and oxidative stress. By further
elucidating the biological pathways by which these drugs
exert their effects, we considered the rationale for choosing
optimal drug combinations that will benefit patients at risk.
The differential effect of CCBs on brachial and central
blood pressure has been explored, along with the future role
of central blood pressure as a prognostic marker for cardio-
vascular disease events. Indeed, clinical hypertension trials
have demonstrated the importance of incorporating meas-
urements of central aortic pressure in their study designs.
This will provide much needed outcome data to support
evidence-based practice. Another important aspect of future
hypertension research is the shift towards studying complex
disease models. From a mechanistic viewpoint, multiple
cardiovascular risk factors act synergistically to exacerbate
endothelial dysfunction, oxidative stress and inflammation,
thereby accelerating the atherosclerotic process. It is there-
fore logical that they should be considered together in global
risk assessment. By further elucidating the underlying bio-
logical pathways and mechanisms that lead to target organ
damage in multiple cardiovascular risk factor models, we
may be able to define new therapeutic targets and develop
novel treatments. Such approaches will continue to require
the scientific community to work together to carry out large-
scale studies and to link the findings from experimental
models with human populations.
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